Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06547255 · ClinicalTrials.gov registry record · Phase 4
Exparel Versus Bupivacaine in Post-operative Pain Control
A Phase 4 study of Liposomal Bupivacaine, sponsored by Case Western Reserve University.
- Completed
- Registry status
- Phase 4
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT06547255: Completed Phase 4 study of Liposomal Bupivacaine, sponsored by Case Western Reserve University.
NCT06547255 is a Phase 4 study of Liposomal Bupivacaine that has completed, run by Case Western Reserve University. The registered enrollment target is 82 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06547255, a Phase 4 study of Liposomal Bupivacaine, has completed, sponsored by Case Western Reserve University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, randomized study to evaluate anaesthetic parameters, postoperative analgesia and oral analgesic consumption comparing exparel (liposomal bupivacaine) vs. standard bupivacaine
Primary Outcome
Post operative pain was assessed using 0-10 Visual Analog Scale (VAS) where 0 indicates no pain and 10 indicates worse imaginable pain. Patients recorded pain score twice daily (morning and evening) for four consecutive post operative days using a standardized at home questionnaire
Conditions Studied
Interventions
- DRUG Bupivacaine liposome injectable suspension
Study Locations (1)
Ohio
- Case Western Reserve University - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2024-08-21 |
| Est. Completion | 2025-07-01 |
| Phase | Phase 4 |
What the finished NCT06547255 record still lists
NCT06547255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Liposomal Bupivacaine appearing as the primary indexed condition, and to 1 intervention - of which Bupivacaine liposome injectable suspension is the first listed.
NCT06547255 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06547255 about?
NCT06547255 is a clinical study titled "Exparel Versus Bupivacaine in Post-operative Pain Control". This is a prospective, randomized study to evaluate anaesthetic parameters, postoperative analgesia and oral analgesic consumption comparing exparel (liposomal bupivacaine) vs. standard bupivacaine
What is the current status of trial NCT06547255?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 82 participants. The study started on 2024-08-21. Estimated completion is 2025-07-01.
What conditions does trial NCT06547255 study?
This clinical trial studies the following conditions: Liposomal Bupivacaine.
What interventions are being tested in trial NCT06547255?
The interventions under investigation include: Bupivacaine liposome injectable suspension (DRUG).
Who is sponsoring clinical trial NCT06547255?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06547255 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06547255's enrollment target sits among peer trials
82 939th of 2000 higher than 1,062 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI